Fading with time of PD-L1 immunoreactivity in non-small cells lung cancer tissues: A methodological study

Applied Immunohistochemistry and Molecular Morphology

Volumn 26, Issue 7, 2018, Pages 489-494

  Giunchi, Francesca ^a   Degiovanni, Alessio ^a   Daddi, Niccolò ^b   Trisolini, Rocco ^b   Dell'Amore, Andrea ^b   Agostinelli, Claudio ^b   Ardizzoni, Andrea ^b   Fiorentino, Michelangelo ^a  

^a Inst of Oncology 'Felice Addarii'   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Immune checkpoint; Immunohistochemestry; NSCLC; PD L1

Indexed keywords

PROGRAMMED DEATH 1 LIGAND 1;

ADENOCARCINOMA; ARTICLE; CANCER THERAPY; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; TEMPERATURE; TISSUE MICROARRAY; TUMOR ASSOCIATED LEUKOCYTE;

EID: 84994078690     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0000000000000458     Document Type: Article

References (20)

1. Chen L. Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol. 2004;4:336-347.
2. Taube JM, Klein A, Brahmer JR. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res. 2014;20: 5064-5074.
3. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252-264.
4. Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol. 2012;24:207-212.
5. Motzer RJ, Escudier B, McDermott DF. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015; 373:1803-1813.
6. Larkin J, Chiarion-Sileni V, Gonzalez R. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373:23-34.
7. Wolchok JD, Kluger H, Callahan MK. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369:122-133.
8. Robert C, Long GV, Brady B. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372: 320-330.
9. Rizvi NA, Mazières J, Planchard D. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): A phase 2, single-arm trial. Lancet Oncol. 2015;16: 257-265.
10. Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372: 2018-2028.
11. Brahmer J, Reckamp KL, Baas P. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373:123-135.
12. Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial. Lancet. 2016;387:1540-1550.
13. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373:1627-1639.
14. Velcheti V, Schalper KA, Carvajal DE, et al. Programmed death ligand-1 expression in non-small cell lung cancer. Lab Invest. 2014;94:107-116.
15. Soria JC, Marabelle A, Brahmer JR, et al. Immune checkpoint modulation for non-small cell lung cancer. Clin Cancer Res. 2015;21:2256-2262.
16. Ott PA, Hodi FS, Robert C. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin Cancer Res. 2013;19: 5300-5309.
17. Konishi J, Yamazaki K, Azuma M, et al. B7-H1 expression on non small cell lung cancer cells and its relationship with tumorinfiltrating lymphocytes and their PD-1 expression. Clin Cancer Res. 2004;10:5094-5100.
18. Mischinger J, Froehlich E, Griesbacher A, et al. Prognostic relevance of B7H1 and B7H3 protein expressions in metastatic clear cell renal cell carcinoma. J Clin Oncol. 2010;28. suppl (May 20 Supplement), 2010: e15074.
19. Schmidt LH, Kümmel A, Görlich D, et al. PD-1 and PD-L1 expression in NSCLC indicate a favorable prognosis in defined subgroups. PLoS One. 2015;10:e0136023.
20. Takada K, Okamoto T, Shoji F, et al. Clinical significance of PD-L1 protein expression in surgically resected primary lung adenocarcinoma. J Thorac Oncol. 2016;pii: S1556-0864 30523-30528.